Praliciguat inhibits progression of diabetic nephropathy in ZSF1 rats and suppresses inflammation and apoptosis in human renal proximal tubular cells.

In conclusion, praliciguat improved proteinuria in the ZSF1 rat model of DN, and its actions in human RPTC suggest that tubular effects may contribute to its renal benefits, building upon strong evidence for the role of cGMP signaling in renal health.
PMID: 32865013 [PubMed - as supplied by publisher]

Source: Am J Physiol Renal P... - August 30, 2020 Category: Urology & Nephrology Authors: Liu G, Shea CM, Jones JE, Price GM, Warren W, Lonie E, Yan S, Currie MG, Profy AT, Masferrer JL, Zimmer DP Tags: Am J Physiol Renal Physiol Source Type: research